
The UK government has chosen to prolong its £330 million agreement with Palantir through 2029, a move that has drawn sharp criticism from opposition lawmakers and advocacy groups. By opting not to invoke a clause that would have allowed termination of the deal in 2025, officials have extended the US company’s role in managing the NHS’ data infrastructure, raising fresh concerns about over-reliance on a single foreign provider.
Peter Griffiths, founder and chairman of Argyll Data Development, cautioned that simply replacing Palantir would fail to resolve broader systemic vulnerabilities unless the government guarantees the NHS maintains full flexibility to migrate its systems and data between different vendors.
Contract Renewal and Data Independence
Griffiths argued that before awarding any future contracts, the government must verify whether patient data, software applications, and essential operations could be transferred seamlessly without compromising care standards. He insisted that “Sovereignty must be a priority for the government, and an exit clause only counts if the NHS can actually leave when it wants to.”
Read Also: FTSE 100 Attracts New Investor Interest
Originally signed in 2023, Palantir’s seven-year contract was intended to create a unified data platform across NHS organizations, with officials claiming it has enabled an additional 110,000 surgical procedures. Yet the extension has intensified fears about NHS systems becoming locked into a single supplier’s ecosystem.
Procurement Policies and Technological Self-Reliance
Dame Chi Onwurah, chair of Parliament’s Science and Technology Committee, condemned the decision as evidence of dangerous overdependence on one company. She called on the government to begin phasing out Palantir immediately rather than deferring action for two more years. While the government plans to launch a replacement procurement process next year, prioritizing British firms, she warned that delays would deepen the NHS’ vulnerability.
The decision to retain Palantir until 2029 has also drawn criticism over the company’s work with the Israeli military and US immigration authorities. While Amnesty International UK hailed the government’s pledge to end the contract, it urged NHS bodies to avoid further integrating the company’s tools pending its full removal. “This is a victory for healthcare workers, patients and campaigners who refused to give up,” said a representative from the organisation. However, they emphasized that the focus must now shift to dismantling Palantir’s presence rather than expanding it.